Skip to main content
Careteq takes $2.96m ATO tax fight to tribunal
Image for illustrative purposes only. Not a real photo.

Careteq takes $2.96m ATO tax fight to tribunal

By

Key points

  • Careteq will ask the Administrative Review Tribunal to review the ATO’s rejection of its objections over R&D tax incentive claims for FY21 to FY23.
  • The ATO is seeking about $2.96 million in refunds and interest, a large sum for a company whose shares are trading at under 1 cent.
  • The company expects to lodge its application within weeks, but said it can’t yet say when the matter will be resolved.

Careteq (ASX:CTQ) will ask the Administrative Review Tribunal to review the Australian Taxation Office’s decision to reject its objections over research and development tax incentive claims for FY21 to FY23.

The ATO issued amended assessments in May 2025 that required Careteq to repay R&D Tax Incentive refunds of $2,615,277.43 and interest of $340,945.52, according to the company’s announcement at the time.

Careteq said that, on advice from its legal counsel MinterEllison, it disagrees with the ATO’s decision, and its board remains convinced that its R&D activities were eligible and its claims valid.

The company will lodge its application with the tribunal, an independent body that reconsiders matters on their merits, over the next few weeks.

Careteq said the timing of a resolution cannot yet be determined. Following the announcement the Careteq share price was $0.009.

The dispute goes back to at least March 2024, when the ATO said in a position paper that Careteq has not provided evidence of adequate substantiation for the expenditure incurred for the R&D activities.

Melbourne-based Careteq is a healthtech company that runs HMR Referrals, a marketplace platform for completing Home Medicines Reviews.


Frequently asked questions